| Similar Articles |
|---|
 |
The Motley Fool
October 5, 2006
Ralph Casale |
RNAi: Nobel Prize-Winning Biotechnology While drugs based on RNAi knockdown technology may have the potential to become the next big thing in biotechnology, they are still a long way from becoming FDA-approved marketable entities. But it's never too soon to start keeping an eye on the future. Investors, take note.   |
Chemistry World
October 2, 2006
Bea Perks |
RNAi Pioneers Win Nobel Prize for Medicine Molecular biologists Andrew Fire and Craig Mello have been awarded this year's Nobel prize in physiology or medicine for their discovery of RNA interference. |
Bio-IT World
November 2006
Kevin Davies |
Merck's $1.1 Billion Bet on RNAi As if the 2006 Nobel Prize in Medicine or Physiology wasn't validation enough, Merck's acquisition of biotech firm Sirna for $1.1 billion last month offered evidence of the commercial implications of RNA interference gene-silencing technology. |
The Motley Fool
November 6, 2006
Ralph Casale |
Validation for a Biotechnology Firm? How Merck's bid to buy a competitor could affect Alnylam Pharmaceuticals. With the recent run-up in share price due to the Merck offer for Sirna, investors should wait for a better price before speculating on Alnylam. |
Chemistry World
November 2006
Bea Perks |
Call That Chemistry? This year's Nobel prize in chemistry was a tour de force for crystallography, underscoring the vital role chemistry plays across the sciences. |
The Motley Fool
November 13, 2006
Jack Uldrich |
Arrowhead: A Long-Term RNAi Play? Its majority stake in Calando Pharmaceuticals could pay dividends. Investors would be wise to continue to watch this company and wait until clinical trials have advanced to a more mature stage before considering an investment. |
Bio-IT World
March 17, 2004 |
IBM: Pedal to the Metal in Healthcare IBM now melds healthcare, life sciences, and IT. |
The Motley Fool
November 16, 2005
Jack Uldrich |
The Next Big Little Market Accelrys' efforts to position itself at the crossroads of nanotech and biotech, and help facilitate new discoveries in those fields through informatics software, could reap considerable rewards for the company and its shareholders. |
BusinessWeek
February 26, 2007
Gene G. Marcial |
CytRx Can 'Silence' Genes That Cause Disease Since October, shares of CytRx have more than doubled as investors zeroed in on its RNA interference technology that targets diabetes, obesity, and ALS. |
Bio-IT World
December 15, 2004
Nancy Weil |
Running Interference The revolution in RNA interference has galvanized basic research. Now, some biopharmas are pushing the technology from the laboratory to the clinic. |
Chemistry World
November 2009
Bibiana Campos-Seijo |
Editorial: Ringing in the Nobels This year the chemistry prize seems to have once again caused a bit of a commotion. The criticism? Well, some in the scientific community have suggested that the research had too strong a biological focus. |
Bio-IT World
July 15, 2003
Malorye Branca |
Silence Is Golden RNA interference's scientific, therapeutic, and economic potential is unquestionable, but some sticky questions still remain. |
The Motley Fool
August 15, 2006
Ralph Casale |
Sirna Battles Genes Gone Bad Pharmaceutical start-up Sirna Therapeutics tests drugs to silence rogue genes. Investors, while drugs based on RNA interference may have the potential to become the next big thing in biotechnology, they're still a long, long way from becoming FDA-approved, marketable entities. |
Bio-IT World
November 2005
Nancy Weil |
Dharmacon, Institutes Form siRNA Global Initiative The company has formed a global alliance with leading biomedical research centers aimed at speeding scientific and medical discoveries now that the first complete siRNA (small interfering RNA) library is available for targeting genes in the human genome. |
The Motley Fool
February 9, 2006
Jason Mac Gurn |
RNA: Rule Breaker Nucleic Acid Investors, new RNA-based technologies may be the next revolution in biopharmaceuticals. ISIS Pharmaceuticals... Sirna Therapeutics... Alnylam Pharmaceuticals... |
Chemistry World
October 7, 2015 |
Live blog: Unravelling DNA repair mechanisms takes chemistry Nobel Our live blog explains the vital statistics of the Nobel chemistry prize and the countdown to the award announcement. |
Chemistry World
November 5, 2007
Lewis Brindley |
Silencing the Pests Two teams of scientists have uncovered a new way to protect crops from two serious insect pests. The teams made use of a process called RNA interference to silence critical genes in the bodies of the insect larvae and stopped them growing. |
Bio-IT World
December 15, 2004
Zachary Zimmerman |
Silence Is Golden Life Science Insights believes that RNAi therapeutics will dramatically affect the pharmaceutical and healthcare industries, becoming the next major class of therapeutics, joining small molecules, proteins, and monoclonal antibodies. |
Bio-IT World
July 11, 2002
Mike Fitzgerald |
Funding the Future Investor G. Steven Burrill, CEO of Burrill & Company, helps biotech companies fulfill their potential. He talked recently about his view of the bio-IT field. |
Chemistry World
November 2011
Bibiana Campos Seijo |
Editorial: Nobels and Nobility The 2011 Nobel prize in chemistry has been awarded to Daniel Shechtman at Technion in Haifa, Israel, for the discovery of quasicrystals. |
HBS Working Knowledge
November 3, 2014
Carmen Nobel |
Brand Lessons From the Nobel Prize What makes the Nobel Prize so coveted? Stephen Greyser and Mats Urde discuss the first field-based study exploring the prize from a brand and reputation perspective. |
Bio-IT World
November 2005
Robert M. Frederickson |
Innovations in Interference RNAi has moved from phenomenon to promising drug in less than five years, but it also has potential to be a tool used in drug discovery. |
Bio-IT World
December 15, 2004
David A. Bumcrot |
Identifying RNAi Drug Candidates Breakthroughs in understanding RNA's extensive role in essential cellular processes have opened up the potential for a whole new class of drugs based on RNAi. |
Bio-IT World
December 15, 2004
William Marshall |
Applications of RNAi RNA interference is a highly coordinated gene regulatory mechanism that appears to be highly conserved across all metazoans studied thus far. |
The Motley Fool
July 11, 2007
Brian Orelli |
Everybody Loves RNAi Roche is the latest firm to (over)pay for the hottest new drug technology. Alnylam announced that it licensed some of its intellectual property to Roche for $331 million. Investors, take note. |
Bio-IT World
August 15, 2005
Kevin Davies |
Hood Hails 'Century of Biology' Leroy Hood won the 2005 Bio-IT World President's Award for his work on the synthesis of DNA and protein, and on the genome project. |
Chemistry World
October 5, 2015 |
Behind closed doors: How to win the Nobel prize Few know the process by which the winner or winners are chosen. We go behind closed doors to find out how the Nobel committee make their selection. |
Chemistry World
April 28, 2008
Victoria Gill |
Gene silencing gets fat A team of researchers in the US has developed fat-like nanoparticles that can carry fragments of RNA into cells, bring treatments based on gene silencing a step closer. |
The Motley Fool
November 30, 2010
Brian Orelli |
RNAi Is On Sale The novel technology looks more promising at these prices. |
Chemistry World
March 21, 2010
Simon Hadlington |
Nanoparticles successfully deliver RNA interference in cancer patients The system aims to exploit the phenomenon of RNA interference, where short sequences of double-stranded RNA, called small interfering RNA or siRNA, can trigger the disruption of the manufacture of certain proteins in a cell. |
The Motley Fool
May 18, 2007
Mike Havrilla |
Ample Opportunities for Alnylam The biotech's RNAi pipeline and cutting-edge technology make it a prime takeover candidate. Investors, take note. |
The Motley Fool
April 5, 2004
Charly Travers |
A Biotech's Transition to Drugs A deal with Roche gives ArQule's drug program a leg up. ArQule has spent the last year transitioning from a services company into a drug developer. Last week's deal with Roche could signify that the transition is complete. |
Chemistry World
November 2, 2015
Philip Robinson |
A Nobel purpose The Nobel categories are fields that support Nobel's humanitarian goals, and looking at this year's awards, there is a notable humanitarian, even humanist, flavor. |
Bio-IT World
November 2005
G. Steven Burrill |
Biotech Posts Strong Third Quarter Despite overall subpar numbers in September, as compared with the previous four months, this was another excellent quarter for biotech... A good quarter for collaborations... IPO windows open slowly... Biotech still attractive for big pharmaceuticals... |
The Motley Fool
August 1, 2007
Brian Orelli |
RNAi Gets Pumped Up Is a collaboration between RNAi expert Alnylam Pharmaceuticals and medical-device maker Medtronic something investors can endorse? |
The Motley Fool
March 27, 2008
Brian Lawler |
A Little Bit of Cash for ArQule Development-stage drugmaker ArQule announces that it has received a milestone payment for discovery-stage drug work that it performed for partner Wyeth. |
The Motley Fool
September 28, 2007
Brian Orelli |
RNAi Doesn't Kill Mice After All From Merck, to AstraZeneca, to Novartis, big pharma continues to pump hundreds of millions of dollars into unproven RNAi technology. Investors, take note. |
